In summary, our findings suggested that combining NRF2 inhibitors and GPX4 inhibitors leads to synergistic inhibition of the growth of ovarian cancer by induction of ferroptosis as well as apoptosis. The gene discussed is GPX4; the disease is ovarian cancer.